BioLife Solutions (BLFS) Q3 2025: Cell Processing Revenue Jumps 33% as Pure Play Model Takes Hold
BioLife Solutions sharpened its focus as a pure play cell processing provider, delivering robust recurring revenue growth and raising full-year guidance after divesting its EVO cold chain unit. Margin expansion and a disciplined capital allocation stance position BLFS for durable growth, though the company faces tougher comps and evolving market dynamics into 2026. Investors should watch for execution on cross-sell initiatives and the impact of further pricing actions as the company leverages its market leadership in biopreservation media.
Summary
- Portfolio Streamlining Unlocks Focus: Divestiture of EVO cold chain sharpens BioLife’s positioning as a high-margin, recurring revenue cell processing pure play.
- Commercial Customer Momentum: Over half of BPM revenue now comes from commercial and late-stage clinical customers, underpinning visibility and stability.
- Margin Expansion Signals Leverage: Operating leverage and selective pricing actions are driving profitability gains despite near-term product mix headwinds.
Business Overview
BioLife Solutions provides biopreservation media (BPM), cell processing tools, and related products to the cell and gene therapy (CGT) industry. The company generates revenue from recurring sales of consumables and instruments used by commercial and clinical-stage CGT developers, with BPM representing the core franchise. Following the sale of the EVO cold chain business, BLFS is now a focused cell processing solutions provider, with commercial and late-stage clinical customers driving the majority of revenue.
Performance Analysis
BioLife posted 31% year-over-year total revenue growth in Q3, led by a 33% surge in cell processing revenue, even after normalizing for a $1.3 million BPM order pulled forward from Q4. The BPM franchise continues to anchor the business, accounting for more than 80% of cell processing revenue (excluding the early shipment), and is deeply embedded in 16 approved therapies and over 250 clinical trials, including 30+ phase three programs. This entrenched position is translating into high recurring revenue and increased commercial customer share.
Adjusted EBITDA margin expanded by 500 basis points year-over-year to 28%, highlighting operating leverage from streamlined operations and a higher mix of direct sales. However, adjusted gross margin dipped to 64% (from 67% prior year) due to a one-time inventory reserve and less favorable product mix, partially offset by pricing actions and improved scale. Operating expenses increased, reflecting higher stock-based compensation and investments in commercial initiatives, but operating income and net income both improved on a GAAP and adjusted basis.
- Customer Mix Shift: Direct sales rose to 70% of BPM revenue, up from 60%, as commercial customers drove nearly half of BPM sales.
- Recurring Revenue Visibility: Top 20 BPM customers accounted for 80% of BPM revenue, providing a stable, predictable base.
- Cash Position Strengthened: Cash and marketable securities reached approximately $125 million post-EVO sale, enhancing flexibility for capital allocation.
Management raised full-year guidance for both cell processing and total revenue, reflecting confidence in sustained momentum and the benefits of a focused portfolio. The company expects a sequential dip in Q4 revenue due to the BPM order timing, but underlying demand remains robust.
Executive Commentary
"We delivered another strong quarter and we are raising our full year 2025 guidance as our team continues to execute and build on the momentum we've seen develop over recent quarters. Importantly, the mix of higher margin recurring revenue continues to translate into improved profitability, with adjusted EBITDA margin expanding 500 basis points year over year to 28%."
Roderick DeGrief, Chief Executive Officer & Chairman of the Board
"Our adjusted revenue guidance includes increasing our self-processing revenue guidance from $91 million to $93 million to $93 million to $94 million, or a 26% to 28% growth rate compared to prior year. We continue to expect adjusted gross margin for the full year to be in the mid-60s, a reduction of gap net loss, and expansion in adjusted EBITDA margin in 2025 when compared to 2024 due to higher expected revenue partially offset by increases in R&D expenses related to development projects."
Troy Witterman, Chief Financial Officer
Strategic Positioning
1. Pure Play Cell Processing Focus
With the $25 million sale of the EVO cold chain platform, BioLife has completed its strategic transformation into a focused cell processing solutions provider. This move eliminates dilution from lower-margin logistics and aligns capital and management attention on core competencies in biopreservation media and adjacent cell processing tools.
2. Commercial Customer Expansion
The company’s growth is increasingly anchored by commercial and late-stage clinical customers, which now contribute over half of BPM revenue. This segment is less exposed to biotech funding volatility and early-stage trial attrition, providing a durable foundation for recurring revenue and improved forecasting visibility.
3. Cross-Sell and Revenue Per Dose Upside
Management is actively pursuing cross-sell opportunities within its top BPM accounts, aiming to expand wallet share with products like cryo case, cell seal, RHPL, and CT5. Success here could double or triple revenue per patient dose, leveraging deep customer relationships and embedded workflows. The sales team remains small and focused, with incremental headcount to be added only as ROI becomes clear.
4. Pricing Power and Margin Discipline
BLFS is executing selective price increases, with 2026 list prices expected to rise 4% to 6% depending on SKU, and has already achieved above-list price growth through contract negotiations. Margin expansion remains a key management priority, with strict discipline around inorganic investments to avoid diluting the improved financial profile.
5. Capital Allocation and Adjacency Exploration
With a fortified balance sheet and the portfolio reset complete, management is exploring M&A and adjacent product opportunities that complement core strengths. However, any inorganic move must clear a high bar for financial accretion and strategic fit, with leadership committed to not sacrificing margin gains for growth.
Key Considerations
BioLife’s Q3 marks the culmination of a two-year strategic overhaul, positioning the company for sustainable, high-margin growth in a maturing CGT market. The quarter’s results and commentary reveal several key considerations for investors:
- Recurring Revenue Foundation: Over 80% of cell processing revenue is recurring, supported by embedded BPM products in approved therapies and late-stage trials.
- Cross-Sell Execution: The ability to convert marquee BPM customers to broader cell processing tools will determine the next leg of revenue growth.
- Pricing Leverage: Management’s confidence in further price increases reflects strong product value but must be balanced against customer budget pressures.
- Capital Deployment Caution: M&A and new product investments will be tightly filtered to protect margin expansion and avoid strategic drift.
- Market Maturity and Visibility: As the CGT space evolves, BioLife’s deep integration in late-stage programs offers resilience, though future growth will depend on continued therapy approvals and patient access expansion.
Risks
BioLife Solutions faces risks from potential slowdowns in therapy approvals, funding volatility in biotech, and customer consolidation or pipeline attrition, which could impact recurring revenue growth. Margin expansion is also exposed to product mix shifts and inflationary pressures, while the company’s small direct sales team may constrain the pace of cross-sell execution. Regulatory, reimbursement, and competitive dynamics in the CGT space remain ongoing uncertainties.
Forward Outlook
For Q4 2025, BioLife guided to:
- Sequential revenue decline due to the $1.3 million BPM order shipped early in Q3
- Stable operating expense baseline post-EVO divestiture
For full-year 2025, management raised guidance:
- Total revenue of $95 million to $96 million (27% to 29% YoY growth, EVO-adjusted)
- Cell processing revenue of $93 million to $94 million (26% to 28% YoY growth)
Management flagged:
- Mid-60s adjusted gross margin target and continued adjusted EBITDA margin expansion
- Incremental price increases in 2026 and robust commercial customer pipeline as key growth drivers
Takeaways
BioLife’s Q3 demonstrates the power of a focused, recurring revenue model and disciplined execution, with margin expansion and improved visibility as immediate benefits.
- Strategic Reset Complete: With EVO divested, BLFS is fully aligned on high-value cell processing and positioned for durable profitability gains.
- Commercial Customer Growth: The shift toward commercial and late-stage clinical customers insulates revenue and supports multi-year growth visibility.
- Cross-Sell and Pricing in Focus: Future upside depends on converting BPM customers to broader tool adoption and maintaining pricing power without sacrificing customer relationships.
Conclusion
BioLife Solutions exits Q3 2025 as a leaner, more focused cell processing leader, with recurring revenue, margin expansion, and capital allocation discipline setting the stage for continued outperformance. The company’s ability to drive cross-sell, execute on pricing, and selectively deploy capital will be the key watchpoints heading into 2026.
Industry Read-Through
BioLife’s results reinforce the value of recurring consumables and embedded solutions in the cell and gene therapy supply chain, especially as the industry matures and therapy approvals scale. The company’s success in shifting to a pure play, high-margin model may prompt peers to reevaluate portfolio focus and capital allocation. For the broader CGT tools and bioprocessing sector, commercial customer concentration and product cross-sell remain critical levers for sustainable growth, while margin management and pricing discipline will separate winners from laggards as competition intensifies and funding cycles fluctuate.